Chronic Ocular Pain Market: By Indication (Dry Eye Disease, Stevens-Johnson Syndrome, Scleritis, Episcleritis, Sjögren's Syndrome, Pterygium, Contact Lens Intolerance, Others); Treatment Type (Pharmacological Treatments (Analgesics, (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Opioids (Corticosteroids, Antibiotics/Antivirals, Mydriatics/Cycloplegics, Others)), Non-Pharmacological Treatments (Physical Therapies (Cold Compresses, Warm Compresses), Home Remedies, Eye Drops, Others); Application (Post-Surgical Pain, Trauma-Induced Pain, Infection-Induced Pain, Others); Route of Administration (Topical, Oral, Injectable); End Users (Hospitals, Opthalmic Clinics, Homecare Settings, Others); Gender (Male and Female); Age Group (Up to 10 Yrs, 10 to 25 Yrs, 25 to 40 Yrs, 41 to 55 Yrs, 55 to 70 Yrs, Above 70 Yrs); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2024–2032
Chronic ocular pain market was valued at US$ 7.19 billion in 2023 and is projected to hit the market valuation of US$ 12.44 billion by 2032 at a CAGR of 6.58% during the forecast period 2024–2032. Read More
We Are Trusted By These Great Companies!
Published On: 23-Nov-2024 | Format: | Report ID: AA1124982